Maria Prendecki
Overview
Explore the profile of Maria Prendecki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erskine F, Spensley K, Prendecki M, Santos E, Anand A, Altmann D, et al.
HLA
. 2025 Feb;
105(2):e70076.
PMID: 39991976
HLA genes exhibit a high degree of polymorphism, contributing to genetic variability known to influence immune responses to infection. Here we investigate associations between HLA polymorphism and serological and T-lymphocyte...
2.
Ferhat M, Mayer J, Costa L, Prendecki M, Tarazona A, Schinagl A, et al.
PLoS One
. 2024 Oct;
19(10):e0311837.
PMID: 39374239
The oxidized form of Macrophage Migration Inhibitory Factor (oxMIF) has been identified as the disease-related isoform of MIF, exerting pathological functions in inflamed tissue. In this study, we aimed to...
3.
Prendecki M, Gurung A, Pisacano N, Pusey C
Immunol Lett
. 2024 Oct;
270:106933.
PMID: 39362307
Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a group of rare systemic autoimmune diseases characterised by necrotising inflammation of small blood vessels and usually associated with circulating ANCA. The pathophysiology...
4.
Goodyear C, Patel A, Barnes E, Willicombe M, Siebert S, I de Silva T, et al.
Lancet Rheumatol
. 2024 May;
6(6):e339-e351.
PMID: 38734019
Background: The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully...
5.
Barnes E, Goodyear C, Willicombe M, Gaskell C, Siebert S, I de Silva T, et al.
Nat Med
. 2023 Jul;
29(7):1760-1774.
PMID: 37414897
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19)...
6.
Gleeson S, Martin P, Thomson T, Spensley K, Goodall D, Bedi R, et al.
Front Immunol
. 2023 Feb;
13:1083167.
PMID: 36726970
SARS-CoV-2 vaccines are recommended pre-transplantation, however, waning immunity and evolving variants mandate booster doses. Currently there no data to inform the optimal timing of booster doses post-transplant, in patients primed...
7.
Prendecki M, Gulati K, Pisacano N, Pinheiro D, Bhatt T, Mawhin M, et al.
Arthritis Rheumatol
. 2022 Nov;
75(1):84-97.
PMID: 36428281
Objective: Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to...
8.
Prendecki M, Willicombe M
Lancet Infect Dis
. 2022 Nov;
23(3):263-264.
PMID: 36354033
No abstract available.
9.
Martin P, Gleeson S, Clarke C, Thomson T, Edwards H, Spensley K, et al.
Lancet Reg Health Eur
. 2022 Sep;
21:100478.
PMID: 36105885
Background: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus...
10.
Thomson T, Prendecki M, Gleeson S, Martin P, Spensley K, De Aguiar R, et al.
EClinicalMedicine
. 2022 Sep;
53:101642.
PMID: 36105874
Background: Solid organ transplant recipients have attenuated immune responses to SARS-CoV-2 vaccines. In this study, we report on immune responses to 3rd- (V3) and 4th- (V4) doses of heterologous and...